Prolonged Viral Shedding of SARS-CoV-2 in Patients With Underlying Haemato-oncological Disease
Alexander Casimir Angleitner, Lena Levien, Judith Büntzel
In Vivo, doi:10.21873/invivo.13887
Patients with hematological malignancies (HM) are more susceptible to developing severe symptoms of COVID19 and infection-associated death (1). Recently, a large retrospective study in Spain reported a twice higher risk of HM patients for severe COVID-19 compared to the general population. This risk was even more pronounced in patients with newly
Conflicts of Interest The Authors have no conflicts of interest in relation to this study.
Authors' Contributions AA and BJ curated and annotated data, prepared figures. All Authors were responsible for data analysis and writing the manuscript as well as revising it. BJ was responsible for the organization and coordination of the project.
Funding The Authors acknowledge support by the Open Access Publication Funds/transformative agreements of the Göttingen University.
References
Aiello, Puerta-Alcalde, Chumbita, Lopera, Monzó et al., Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals, J Antimicrob Chemother,
doi:10.1093/jac/dkad105Basquiera, García, Martinez Rolón, Olmedo, Laviano et al., Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: a report from the Argentine Society of Hematology, Medicina (B Aires)
Cevik, Tate, Lloyd, Maraolo, Schafers et al., SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis, Lancet Microbe,
doi:10.1016/S2666-5247(20)30172-5Colaneri, Pieri, Roda, Ricciardi, Gotti et al., Assessing the efficacy of early therapies against SARS-CoV-2 in hematological patients: a reallife study from a COVID-19 referral centre in Northern Italy, J Clin Med,
doi:10.3390/jcm11247452Gupta, Desai, Sanjeev, Chauhan, Nityanand et al., Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India, Ann Hematol,
doi:10.1007/s00277-021-04644-3Gur, Giladi, Isenberg, Neuberger, Stern, COVID-19 in patients with hematologic malignancies: clinical manifestations, persistence, and immune response, Acta Haematol,
doi:10.1159/000523872He, Fang, Yang, Association between immunity and viral shedding duration in non-severe SARS-CoV-2 Omicron variant-infected patients, Front Public Health,
doi:10.3389/fpubh.2022.1032957Levy, Lavi, Zimran, Grisariu, Aumann et al., COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome, Leuk Lymphoma,
doi:10.1080/10428194.2021.1966782Li, Zhou, Ma, Zhang, Shao et al., The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID, Signal Transduct Target Ther,
doi:10.1038/s41392-023-01640-zMendes-Correa, Salomão, Ghilardi, Tozetto-Mendoza, Villas-Boas et al., SARS-CoV-2 detection and culture in different biological specimens from immunocompetent and immunosuppressed COVID-19 patients infected with two different viral strains, Viruses,
doi:10.3390/v15061270Mittelman, Barda, Dagan, Oster, Leader et al., Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting, Blood,
doi:10.1182/blood.2021013768Nussenblatt, Roder, Das, De Wit, Youn et al., Yearlong COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B-cell depletion, J Infect Dis,
doi:10.1093/infdis/jiab622Pagano, Salmanton-García, Marchesi, Busca, Corradini et al., EPICOVIDEHA working group: COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA), J Hematol Oncol,
doi:10.1186/s13045-021-01177-0Passamonti, Cattaneo, Arcaini, Bruna, Cavo et al., Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study, Lancet Haematol,
doi:10.1016/S2352-3026(20)30251-9Roel, Pistillo, Recalde, Fernández-Bertolín, Aragón et al., Cancer and the risk of coronavirus disease 2019 diagnosis, hospitalisation and death: A population-based multistate cohort study including 4 618 377 adults in Catalonia, Spain, Int J Cancer,
doi:10.1002/ijc.33846Steiner, Schwarz, Corman, Gebert, Kleinschmidt et al., SARS-CoV-2 T cell response in severe and fatal COVID-19 in primary antibody deficiency patients without specific humoral immunity, Front Immunol,
doi:10.3389/fimmu.2022.840126Tarabay, Babiker, Adelman, Stittleburg, Varkey et al., Immuno compromised patients with prolonged viral shedding of SARS-COV-2, Open Forum Infect Dis,
doi:10.1093/ofid/ofab466.480Visco, Marcheselli, Mina, Sassone, Guidetti et al., ITA-HEMA-COV investigators: A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study, Blood Adv,
doi:10.1182/bloodadvances.2021005691Zonozi, Walters, Shulkin, Naranbhai, Nithagon et al., T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19, Sci Transl Med,
doi:10.1126/scitranslmed.adh4529DOI record:
{
"DOI": "10.21873/invivo.13887",
"ISSN": [
"0258-851X",
"1791-7549"
],
"URL": "http://dx.doi.org/10.21873/invivo.13887",
"accepted": {
"date-parts": [
[
2024,
12,
13
]
]
},
"alternative-id": [
"10.21873/invivo.13887"
],
"author": [
{
"affiliation": [],
"family": "ANGLEITNER",
"given": "ALEXANDER CASIMIR",
"sequence": "first"
},
{
"affiliation": [],
"family": "LEVIEN",
"given": "LENA",
"sequence": "additional"
},
{
"affiliation": [],
"family": "BÜNTZEL",
"given": "JUDITH",
"sequence": "additional"
}
],
"container-title": "In Vivo",
"container-title-short": "In Vivo",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2025,
2,
26
]
],
"date-time": "2025-02-26T13:50:17Z",
"timestamp": 1740577817000
},
"deposited": {
"date-parts": [
[
2025,
3,
15
]
],
"date-time": "2025-03-15T14:45:53Z",
"timestamp": 1742049953000
},
"indexed": {
"date-parts": [
[
2025,
3,
15
]
],
"date-time": "2025-03-15T15:10:18Z",
"timestamp": 1742051418790,
"version": "3.38.0"
},
"is-referenced-by-count": 0,
"issue": "2",
"issued": {
"date-parts": [
[
2025,
2,
26
]
]
},
"journal-issue": {
"issue": "2",
"published-online": {
"date-parts": [
[
2025,
2,
26
]
]
},
"published-print": {
"date-parts": [
[
2025,
3
]
]
}
},
"language": "en",
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.21873/invivo.13887",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "9336",
"original-title": [],
"page": "844-850",
"prefix": "10.21873",
"published": {
"date-parts": [
[
2025,
2,
26
]
]
},
"published-online": {
"date-parts": [
[
2025,
2,
26
]
]
},
"published-print": {
"date-parts": [
[
2025,
3
]
]
},
"publisher": "Anticancer Research USA Inc.",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "http://iv.iiarjournals.org/lookup/doi/10.21873/invivo.13887"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Prolonged Viral Shedding of SARS-CoV-2 in Patients With Underlying Haemato-oncological Disease",
"type": "journal-article",
"volume": "39"
}
